IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 4773 
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2418    
    Printed49    
    Emailed0    
    PDF Downloaded97    
    Comments [Add]    
    Cited by others 2    

Recommend this journal

 

 DRUG WATCH
Year : 2014  |  Volume : 46  |  Issue : 1  |  Page : 125-126

Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma


1 Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey
2 Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

Correspondence Address:
Mehmet A. N. Sendur
Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0253-7613.125195

Rights and Permissions

Bevacizumab is a recombinant humanized monoclonal antibody that selectively blocks the activity of vascular endothelial growth factor (VEGF) receptor and it is used in metastatic colorectal patients. We present here a case of fatal necrotizing fasciitis in a patient during bevacizumab treatment for colorectal cancer. In our review of the literature, necrotizing fasciitis was not reported before or during bevacizumab treatment.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow